Bristol Myers Squibb presents 56-week Camzyos trial data
What it means
- What to watch: Drugmakers live and die by pipelines — what is in late-stage trials matters more than this quarter's sales.
- How the stock is trading: $BMY -1.38% in the latest session.
- Timing: It landed after the closing bell, so the session change beside it was locked in before the story existed. The next session is the first that could react.
Where the stock stands
$BMY last traded at $62.26, -1.38% on the session. That puts it 9.3% shy of its 52-week high of $68.64 and 38% clear of its low of $45.27 — in the upper part of the range. Over the year it has ranged 52% from low to high: a wide band, so a several-percent week is just a week. These are latest-session quotes, not live prices — the live tape is on the $BMY page.
How much coverage it is getting
This is the only story Wook has logged on $BMY in the last 30 days — a quiet name that just got a headline. 12 related stories — same name or same desk — are lined up beside this one if you want the whole thread.
The bigger picture
Healthcare stories turn on approvals, trial data and pricing: one FDA decision or trial readout can swing a single drugmaker hard, while drug-pricing policy moves the whole group at once. Wook's supply-chain scanner has Health Care reading calm today: no unusual stress in the filings and disclosures it watches.
What to watch next
The $BMY page has the full chart, the filings and the valuation model behind every figure here. Because one outlet dominates the coverage, reading another outlet on the same story is the quickest check on whether it is being confirmed or just repeated. And Wook AI, up top, will happily do the math — how far $BMY sits from its high, or how this week's coverage stacks up.
How this analysis was made
Investing.com published it, and Wook filed it under Healthcare & Pharma. No strongly worded term either way, so it reads neutral at low severity — a factual headline rather than a charged one. It was matched to $BMY. The publisher gave no preview text, and nothing has been written in to fill the gap.
The tone and severity labels come from a fixed word list — no editor, no AI, no crystal ball — so they describe how a story is worded, not what happens next. They are not a forecast or a recommendation, and a same-day move does not mean this story caused it. Not investment advice.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Investing.com published this on November 6, 2026. $BMY has moved +0.19% ($62.14 to $62.26). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.